2017 Q2 Form 10-Q Financial Statement
#000114420417024582 Filed on May 04, 2017
Income Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| Revenue | $2.917M | $2.712M | $0.00 |
| YoY Change | 52.09% | -100.0% | |
| Cost Of Revenue | $1.524M | $1.459M | $973.7K |
| YoY Change | 34.22% | 49.81% | 17.32% |
| Gross Profit | $1.393M | $1.253M | $0.00 |
| YoY Change | 78.13% | -100.0% | |
| Gross Profit Margin | 47.75% | 46.2% | |
| Selling, General & Admin | $3.026M | $2.773M | $3.060M |
| YoY Change | 15.27% | -9.38% | 54.55% |
| % of Gross Profit | 217.25% | 221.31% | |
| Research & Development | $230.7K | $249.8K | $144.5K |
| YoY Change | 69.91% | 72.93% | 60.53% |
| % of Gross Profit | 16.56% | 19.94% | |
| Depreciation & Amortization | $180.0K | $131.6K | $72.90K |
| YoY Change | 80.0% | 80.44% | 82.26% |
| % of Gross Profit | 12.92% | 10.5% | |
| Operating Expenses | $3.257M | $3.023M | $144.5K |
| YoY Change | 17.96% | 1992.23% | -92.99% |
| Operating Profit | -$1.864M | -$1.769M | $0.00 |
| YoY Change | -5.81% | -100.0% | |
| Interest Expense | $26.00 | $15.67K | -$80.00K |
| YoY Change | -99.88% | -119.58% | -66.67% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $3.463K | $0.00 | $0.00 |
| YoY Change | -280.84% | ||
| Pretax Income | -$1.860M | -$1.785M | -$2.710M |
| YoY Change | -52.69% | -34.13% | 39.69% |
| Income Tax | $0.00 | $4.231K | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$1.860M | -$1.789M | $0.00 |
| YoY Change | -52.73% | -100.0% | |
| Net Earnings / Revenue | -63.76% | -65.97% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$77.60K | -$101.7K | -$256.1K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 23.98M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $12.90M | $14.50M | $2.800M |
| YoY Change | 186.67% | 417.86% | 100.0% |
| Cash & Equivalents | $12.85M | $14.53M | $2.793M |
| Short-Term Investments | |||
| Other Short-Term Assets | $300.0K | $300.0K | $200.0K |
| YoY Change | 0.0% | 50.0% | 105.47% |
| Inventory | $100.0K | $70.96K | $69.80K |
| Prepaid Expenses | |||
| Receivables | $1.300M | $1.468M | $1.021M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $14.49M | $16.39M | $4.132M |
| YoY Change | 145.54% | 296.73% | 91.13% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.312M | $2.100M | $1.320M |
| YoY Change | 65.12% | 59.12% | 328.59% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $400.0K | $400.0K | $400.0K |
| YoY Change | 0.0% | 0.0% | |
| Total Long-Term Assets | $2.705M | $2.507M | $1.692M |
| YoY Change | 50.27% | 48.19% | 280.38% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $14.49M | $16.39M | $4.132M |
| Total Long-Term Assets | $2.705M | $2.507M | $1.692M |
| Total Assets | $17.19M | $18.90M | $5.824M |
| YoY Change | 123.27% | 224.53% | 123.42% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.400M | $1.700M | $1.300M |
| YoY Change | 0.0% | 30.77% | 62.5% |
| Accrued Expenses | $600.0K | $400.0K | $500.0K |
| YoY Change | 50.0% | -20.0% | -28.57% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | $0.00 | $600.0K | $400.0K |
| YoY Change | -100.0% | 50.0% | |
| Total Short-Term Liabilities | $2.000M | $2.634M | $2.174M |
| YoY Change | -23.08% | 21.19% | -27.46% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $600.0K |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $200.0K | $200.0K | |
| YoY Change | |||
| Total Long-Term Liabilities | $200.0K | $200.0K | $600.0K |
| YoY Change | -66.67% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.000M | $2.634M | $2.174M |
| Total Long-Term Liabilities | $200.0K | $200.0K | $600.0K |
| Total Liabilities | $2.200M | $2.834M | $2.728M |
| YoY Change | -15.38% | 3.87% | -9.76% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$127.2M | -$113.1M | |
| YoY Change | 15.71% | ||
| Common Stock | $142.2M | $141.4M | $116.2M |
| YoY Change | 21.63% | 19.39% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $15.03M | $16.07M | $3.096M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $17.19M | $18.90M | $5.824M |
| YoY Change | 123.27% | 224.55% | 123.42% |
Cashflow Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.860M | -$1.789M | $0.00 |
| YoY Change | -52.73% | -100.0% | |
| Depreciation, Depletion And Amortization | $180.0K | $131.6K | $72.90K |
| YoY Change | 80.0% | 80.44% | 82.26% |
| Cash From Operating Activities | -$570.0K | -$829.9K | -$1.970M |
| YoY Change | -60.69% | -57.87% | 52.71% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$410.0K | $631.1K | -$410.0K |
| YoY Change | -311.5% | -253.92% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$410.0K | -$641.3K | -$410.0K |
| YoY Change | 115.79% | 56.41% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $11.57M | $0.00 | |
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -700.0K | $11.48M | -80.00K |
| YoY Change | -120.71% | -14449.42% | -104.17% |
| NET CHANGE | |||
| Cash From Operating Activities | -570.0K | -$829.9K | -1.970M |
| Cash From Investing Activities | -410.0K | -$641.3K | -410.0K |
| Cash From Financing Activities | -700.0K | $11.48M | -80.00K |
| Net Change In Cash | -1.680M | $10.01M | -2.460M |
| YoY Change | -196.55% | -506.84% | -490.48% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$570.0K | -$829.9K | -$1.970M |
| Capital Expenditures | -$410.0K | $631.1K | -$410.0K |
| Free Cash Flow | -$160.0K | -$1.461M | -$1.560M |
| YoY Change | -90.27% | -6.35% | 20.93% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
2431531 | USD |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
17604 | USD |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
129196680 | USD |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-123533882 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5680402 | USD |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8111933 | USD |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14532860 | USD |
| CY2017Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1467849 | USD |
| CY2017Q1 | us-gaap |
Inventory Net
InventoryNet
|
70960 | USD |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
16393088 | USD |
| CY2017Q1 | us-gaap |
Deposits Assets
DepositsAssets
|
363403 | USD |
| CY2017Q1 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
563842 | USD |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2634171 | USD |
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
2833530 | USD |
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
141366712 | USD |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16067557 | USD |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
18901087 | USD |
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
321419 | USD |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
286919 | USD |
| CY2017Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
199359 | USD |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
200264 | USD |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
2712234 | USD |
| CY2016Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1555545 | USD |
| CY2017Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1458737 | USD |
| CY2016Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
973738 | USD |
| CY2017Q1 | us-gaap |
Gross Profit
GrossProfit
|
1253497 | USD |
| CY2016Q1 | us-gaap |
Gross Profit
GrossProfit
|
581807 | USD |
| CY2016Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-40236 | USD |
| CY2017Q1 | cyrx |
Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
|
P90D | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
249843 | USD |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
144478 | USD |
| CY2017Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
131551 | USD |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
72904 | USD |
| CY2017Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
6130 | USD |
| CY2016Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
66055 | USD |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
770442 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
788943 | USD |
| CY2017Q1 | us-gaap |
Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
|
-17238 | USD |
| CY2016Q1 | us-gaap |
Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
|
-131465 | USD |
| CY2017Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
0 | USD |
| CY2016Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
2503 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
|
272370 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
|
406717 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-18539 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
55197 | USD |
| CY2017Q1 | cyrx |
Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
|
0 | USD |
| CY2016Q1 | cyrx |
Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
|
26901 | USD |
| CY2017Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
10199 | USD |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
34500 | USD |
| CY2017Q1 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD |
| CY2016Q1 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
1068055 | USD |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
75000 | USD |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
60000 | USD |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2017Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
|
554300 | USD |
| CY2017Q1 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
9600 | USD |
| CY2016Q1 | us-gaap |
Interest Expense Related Party
InterestExpenseRelatedParty
|
15100 | USD |
| CY2017Q1 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
9600 | USD |
| CY2016Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
11400 | USD |
| CY2017Q1 | cyrx |
Consulting Service Fee
ConsultingServiceFee
|
69000 | USD |
| CY2016Q4 | us-gaap |
Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
|
646700 | USD |
| CY2017Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.88 | |
| CY2017Q1 | us-gaap |
Legal Fees
LegalFees
|
5000 | USD |
| CY2017Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2017Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | |
| CY2017Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2017Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
Cryoport, Inc. | |
| CY2017Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001124524 | |
| CY2017Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2017Q1 | dei |
Trading Symbol
TradingSymbol
|
CYRX | |
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
23975685 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23937696 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23937696 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
17604283 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
17604283 | shares |
| CY2017Q1 | us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
165990 | USD |
| CY2016Q1 | us-gaap |
Liabilities Assumed1
LiabilitiesAssumed1
|
0 | USD |
| CY2017Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
54707 | shares |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
675679 | shares |
| CY2017Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 2. Nature of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material.  Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical <font style="WIDOWS: 2; TEXT-TRANSFORM: none; FONT-STYLE: normal; TEXT-INDENT: 32px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT-FAMILY: 'Times New Roman', Times, serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; COLOR: rgb(0,0,0); FONT-SIZE: 13px; FONT-WEIGHT: normal; WORD-SPACING: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> and biotechnology</font> companies, contract manufacturers and university researchers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is a Nevada corporation and its <font style="BACKGROUND: transparent"> common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”</font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2500000 | shares |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
11571914 | USD |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD |
